191 related articles for article (PubMed ID: 21810917)
1. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Herold CI; Chadaram V; Peterson BL; Marcom PK; Hopkins J; Kimmick GG; Favaro J; Hamilton E; Welch RA; Bacus S; Blackwell KL
Clin Cancer Res; 2011 Sep; 17(18):6061-70. PubMed ID: 21810917
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
Mayer EL; Baurain JF; Sparano J; Strauss L; Campone M; Fumoleau P; Rugo H; Awada A; Sy O; Llombart-Cussac A
Clin Cancer Res; 2011 Nov; 17(21):6897-904. PubMed ID: 21903773
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
8. Gene signature-guided dasatinib therapy in metastatic breast cancer.
Pusztai L; Moulder S; Altan M; Kwiatkowski D; Valero V; Ueno NT; Esteva FJ; Avritscher R; Qi Y; Strauss L; Hortobagyi GN; Hatzis C; Symmans WF
Clin Cancer Res; 2014 Oct; 20(20):5265-71. PubMed ID: 25172932
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of dasatinib in advanced melanoma.
Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib in solid tumors.
Kim LC; Rix U; Haura EB
Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Miller AA; Pang H; Hodgson L; Ramnath N; Otterson GA; Kelley MJ; Kratzke RA; Vokes EE;
J Thorac Oncol; 2010 Mar; 5(3):380-4. PubMed ID: 20087228
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Brooks HD; Glisson BS; Bekele BN; Johnson FM; Ginsberg LE; El-Naggar A; Culotta KS; Takebe N; Wright J; Tran HT; Papadimitrakopoulou VA
Cancer; 2011 May; 117(10):2112-9. PubMed ID: 21523723
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]